Prior TB infection protects across different bacterial lineages

Tuberculosis remains a global health challenge, and one central question is how well the immune memory caused by a first infection protects against later exposures to different forms of the bacterium. JoAnne L. Flynn and colleagues approached this problem by asking whether protection built from one strain of Mycobacterium tuberculosis (Mtb) would work against a genetically distinct strain. The researchers focused on two very different Mtb lineages: a Lineage 4 Erdman strain used for the initial infection, and a Lineage 2 strain called HT-L2 used for a later re-challenge. HT-L2 belongs to a clade that epidemiologists have observed spreading successfully in Lima, Peru over the last decade, which makes this question directly relevant to real-world spread. To model repeated exposure and test immune memory, the team used cynomolgus macaques, an animal model often used for TB research because their immune responses resemble those in people. The study was designed as a heterologous reinfection experiment — that is, the second exposure involved a different genetic lineage than the first — so it could reveal whether prior infection gives broad protection or whether memory is narrowly focused on a single strain.

To measure what happened after the second exposure, the team combined microbiologic analysis, PET-CT imaging and sequencing of Mtb genomic barcodes to track infection in detail. The animals first received the Lineage 4 Erdman Mtb strain, and after a period of established primary infection they were re-challenged with the Lineage 2 strain, HT-L2. Using microbiologic methods, the researchers monitored bacterial infection and spread. PET-CT imaging allowed them to see and count lung lesions and to follow disease activity in the chest. Sequencing of Mtb genomic barcodes let the team distinguish bacteria from the original infection and from the re-challenge so they could tell which strain was causing new lesions. When outcomes were compared with macaques that had been naïve to Mtb before exposure, the reinfected animals had fewer lung lesions and showed better control of both pulmonary and disseminated infection. These combined methods provided consistent evidence that prior infection reduced disease caused by a genetically different Mtb strain.

The central takeaway is that protection against reinfection was not limited by Mtb lineage in this model, a finding that has hopeful implications for TB control. If immune memory raised by one strain can reduce disease from a different, genetically distant strain, then vaccines designed to stimulate broad immune responses may be effective across varied populations and corners of the world. The observation that HT-L2 has been spreading in Lima, Peru underscores the practical importance of protecting against diverse strains, since successful clades can circulate widely. By showing cross-lineage protection in cynomolgus macaques, JoAnne L. Flynn and her team provide experimental support for a concept that epidemiologists and vaccine developers need to consider: immune responses do not always fail against new lineages. While further work will be needed to translate these findings into human vaccine strategies and public health plans, the study offers a clear rationale for pursuing vaccines and interventions aimed at broad protection against multiple Mtb lineages.